Relmada Therapeutics
RLMD
91 hedge funds and large institutions have $40.3M invested in Relmada Therapeutics in 2023 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 26 increasing their positions, 33 reducing their positions, and 30 closing their positions.
90% more call options, than puts
Call options by funds: $307K | Put options by funds: $162K
4.49% less ownership
Funds ownership: 63.6% → 59.11% (-4.5%)
17% less funds holding
Funds holding: 110 → 91 (-19)
21% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 33
43% less capital inflows, than outflows
Capital inflows: $6.73M | Capital outflows: $11.8M
70% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Palo Alto Investors
Palo Alto,
California
|
+$1.87M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.38M |
| 3 |
Parsons Capital Management
Providence,
Rhode Island
|
+$779K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$417K |
| 5 |
Guild Investment Management
Los Angeles,
California
|
+$358K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.96M |
| 2 |
Sio Capital Management
New York
|
-$822K |
| 3 |
Walleye Capital
New York
|
-$728K |
| 4 |
HRT Financial
New York
|
-$552K |
| 5 |
Morgan Stanley
New York
|
-$486K |
RLMD Hedge Fund Activity: Q1 2023 in Review
91 of the 6,286 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q1 2023, worth a combined $40.3M — down 40% from $66.8M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of RLMD and 9 opened new positions — a net loss of 21 holders — while 33 trimmed existing stakes and 26 added.
The largest buyer was Palo Alto Investors, opening a new position worth an estimated $1.87M. The largest seller was Millennium Management, cutting an estimated $2.96M.
- 91 institutional investors held Relmada Therapeutics (RLMD) as of Q1 2023, down from 110 in Q4 2022.
- Funds reported $40.3M of Relmada Therapeutics stock for Q1 2023, down 40% quarter-over-quarter.
- 9 funds opened new Relmada Therapeutics positions in Q1 2023 and 30 closed out, a net change of -21 holders.
- The largest Relmada Therapeutics buyer in Q1 2023 was Palo Alto Investors, an estimated $1.87M added.
- The largest Relmada Therapeutics seller in Q1 2023 was Millennium Management, an estimated $2.96M sold.
Based on aggregated 13F filings for Q1 2023.